MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.410
-0.070 (-4.73%)
At close: Mar 20, 2026, 4:00 PM EDT
1.394
-0.016 (-1.17%)
After-hours: Mar 20, 2026, 7:57 PM EDT
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,801,778
Market Cap
294.82K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | 7 | -5 | -41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| KALA BIO | 38 |
| Aditxt | 26 |
| Virax Biolabs Group | 19 |
| Dermata Therapeutics | 8 |
| CDT Equity | 6 |
| CNS Pharmaceuticals | 5 |
| OKYO Pharma | 4 |
MTVA News
- 4 days ago - MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control - PRNewsWire
- 10 days ago - MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 - PRNewsWire
- 18 days ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PRNewsWire
- 4 weeks ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PRNewsWire
- 5 weeks ago - MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug - Benzinga
- 5 weeks ago - MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 - PRNewsWire
- 6 weeks ago - MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel - PRNewsWire
- 2 months ago - MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option - PRNewsWire